✦ LIBER ✦

Overview of safety of non-biologic and biologic DMARDs

✍ Scribed by Ruderman, E. M.

Book ID: 119975247
Publisher: Oxford University Press
Year: 2012
Tongue: English
Weight: 86 KB
Volume: 51
Category: Article
ISSN: 1462-0324
DOI: 10.1093/rheumatology/kes283

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

OVERVIEW OF BIOLOGIC FACTORS

✍ Silk, Kenneth R. 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 980 KB

Safety of biologic therapy

✍ Wojciech Blonski; Gary R. Lichtenstein 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 207 KB

Several biologic agents have been assessed in patients with inflammatory bowel disease (IBD; Crohn's disease [CD] and ulcerative colitis [UC]). Until recently, only infliximab (humanized monoclonal anti-TNF-alpha antibody) had been approved by the Food and Drug Administration (FDA) to induce and mai

Overview of biologic agents in medicine

Overview of biologic agents in medicine and dermatology

✍ Jeffrey M. Sobell 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 332 KB

Overview of the biologic determinants of

Overview of the biologic determinants of plaque instability

✍ Libby, Peter 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 113 KB

Safety of biologic therapy in rheumatoid

Safety of biologic therapy in rheumatoid arthritis

✍ Woodrick, Robert S.; Ruderman, Eric M. 📂 Article 📅 2011 🏛 Nature Publishing Group 🌐 English ⚖ 619 KB

Overview of biologic therapies in autoim

Overview of biologic therapies in autoimmune rheumatic diseases

✍ Mouyis, Maria; Isenberg, David 📂 Article 📅 2014 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 93 KB